Extrapolation of these doses to humans, using standard allometric conversion factors (factor of 6.2 for rats), yields theoretical doses on the order of 1.6 g/kg in humans
This sounds trivial
In a trial of patients with T2DM and a BMI of 27 kg/m2 or greater being treated with semaglutide injection for weight loss, clinically significant hypoglycemia (plasma glucose less than 54 mg/dL) was reported in 6.2% of semaglutide-treated patients versus 2.5% of placebo-treated patients
Coskun et al., LY3437943, a novel triple glucagon, GIP, and GLP- 1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept, Cell Metab., vol
BPC-157 Peptide Alternatives End Note BPC-157 stands for Body Protection Compound 157 and is a synthetic gut peptide a peptide just being a chain of amino acids made of 15 amino acids
However, as research progressed, its therapeutic potential expanded beyond gastrointestinal applications